First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
Hoffmann-La Roche
Siow Ming Lee; Christian Schulz; Kumar Prabhash; Dariusz Kowalski; Aleksandra Szczesna; Baohui Han; Achim Rittmeyer; Toby Talbot; David Vicente; Raffaele Califano; Diego Cortinovis; Anh Tuan Le; Dingzhi Huang; Geoffrey Liu; Federico Cappuzzo; Jessica Reyes Contreras; Martin Reck; Ramon Palmero; Milena Perez Mak; Youyou Hu; Stefanie Morris; Elen Höglander; Mary Connors; Alice M Biggane; Hans Kristian Vollan; Solange Peters